History
Documents created during the development process.
Background information
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Appendix A - RPP decision paper March 2015
-
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix A matrix of stakeholders
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix B - GE proposal paper January 2015
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (scoping)
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (scoping)
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (guidance development)
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (guidance development)
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final appraisal determination
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final appraisal determination document
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): consultee and commentator comments on the ACD
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Amgen
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Merck Serono
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Roche Products
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Nursing
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Pathologists
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Department of Health
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appraisal consultation
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appraisal consultation
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): evaluation report
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): overview
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): addendum to the assessment report
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendices
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): consultee and commentator comments on the assessment report
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Amgen
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Merck Serono
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Roche
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Nursing
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Pathologists
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Physicians
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Department of Health
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): response to consultee and commentator comments on the assessment report
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): manufacturer submissions (executive summary only)
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Amgen
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Merck Serono
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Roche
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): non-manufacturer submission
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Beating Bowel Cancer
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Bowel Cancer UK
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): expert written personal statements
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Beaumont
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Hochhauser
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Ilyas
-
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Moss
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): protocol
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): protocol
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final scope
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final scope
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final matrix
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final matrix
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): comments on the draft scope
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): comments on the draft scope
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Comments on the provisional matrix
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Comments on the provisional matrix
-
Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): draft scope
-
Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): draft scope
-
Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): provisional matrix
-
Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): provisional matrix
-